Clinical Trial Search

Primary: Hospital Mortality Rate — 6; 2 Participants

Primary: Percent Agreement Between Coronary Calcium Score (CCS) and National Cholesterol Education Program (NCEP) Guidelines — 18 percent agreement

Primary: Number of LDLR Gene Mutations — 7 gene mutations

Primary: High-sensitivity C-reactive Protein — 1.0; 1.0 mg/dl — p=0.22

Primary: Comparison Between Coronary-artery-disease Group and Non-coronary-artery-disease Group on MIF Concentration — 48.08; 66.79 MIF Concentration,ug/L

Primary: Change From Baseline in % Flow Mediated Dilatation (FMD) — 0.09; 0.32 %FMD

Primary: Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks — 8.1; 13.4 Percent change from rest measurement

Primary: Latent Dirichlet Allocation (LDA) Topics - Topics / Themes Discussed Between Patients With and Without Heart Disease — 0.85; 0.87; 0.55; 0.67 proportion probability AUC…

Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale

Primary: Absolute Change From Baseline in HDL-C — 12.76; 0.50 mg/dL

Primary: Complement C3 Genotype — 22; 45; 2; 6 Participants

Primary: Change in Clinicians' Treatment Decision After Age/Sex/Gene Expression Score — 38; 1; 1; 0 number of subjects — p=<0.001

Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1

Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants

Primary: Myocardial Perfusion — 1.83; 1.52 myocardial perfusion index

Primary: Age in Study Participants — 70.6; 77.8 years

Primary: Percent Change From Baseline in Mean Wall Thickness — 4.245; 6.679 Percent Change

Primary: Adherence to Refills and Medications Scale (ARMS) — 12.03; 12.18 units on a scale

Primary: Compliance Questionnaire Scores of the Participants — 22.25; 22.53 score on a scale

Primary: Change in Serum Thromboxane B2 — 5.02; 2.78 ng/mL — p=0.005

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 17; 10; 11; 12 Participants

Primary: Percent Change From Baseline in HDL-C — 33.76; 3.69 Percentage Change of HDL-C

Primary: Feasibility as Measured by the Number of Total Scheduled Intervention Sessions (CHW Counseling Sessions, Doctor's Visits, Phone Calls) Attended — 589 Scheduled sessions

Primary: Percentage Change in Coronary Artery Diameter — 3; 3 % change coronary artery diameter

Primary: Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV) — 14.1 Percent Change

Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…

Primary: Women With Known CAD Who Are Hyporesponsive to Low Dose (81 mg) Aspirin — 0 participants

Primary: Cholesterol Efflux Capacity (CEC) — 1.30; 0.65 Ratio

Primary: Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level — 678 Participants

Primary: Changes in Platelet Function in Response to Clopidogrel — 38.51; 14.06 percentage of maximum aggregation change